GSK admits 70,759 new shares to London market

GSK plc reports that additional ordinary shares have been admitted to trading on the London Stock Exchange Main Market under existing block listing arrangements.

Rhea-AI Filing Summary

GSK plc reports that additional ordinary shares have been admitted to trading on the London Stock Exchange Main Market under existing block listing arrangements. The admission relates to the GlaxoSmithKline plc Share Save Plan 2022.

70,759 Ordinary Shares of 31¼ pence each were admitted, increasing the total number of Ordinary Shares admitted to trading to 4,316,292,310. The notification covers the period from 29 May 2026 to 24 July 2026, and the new shares are fully fungible with existing Ordinary Shares.

Key Figures

Additional shares admitted: 70,759 shares Total shares after admission: 4,316,292,310 shares Nominal value per share: 31¼ pence +1 more

4 metrics

Additional shares admitted 70,759 shares Further Ordinary Shares admitted to trading under block listing

Total shares after admission 4,316,292,310 shares Total Ordinary Shares admitted to trading following this admission

Nominal value per share 31¼ pence Nominal value of each Ordinary Share

Notification date range 29 May 2026 - 24 July 2026 Period covered by the admission to trading notification

Key Terms

block listing admissions, Share Save Plan, fungible, foreign private issuer

4 terms

block listing admissions regulatory

"admitted to trading under existing block listing admissions of Ordinary Shares"

Share Save Plan financial

"in connection with the "GlaxoSmithKline plc Share Save Plan 2022""

fungible financial

"Fungibility | Fully fungible with existing Ordinary Shares"

Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GSK (GSK) disclose about new shares on the London Stock Exchange?

GSK disclosed the admission to trading of 70,759 Ordinary Shares on the London Stock Exchange Main Market. These shares arise under the GlaxoSmithKline plc Share Save Plan 2022 and are admitted under existing block listing arrangements, becoming fully fungible with existing Ordinary Shares.

How many GSK (GSK) shares are now admitted to trading after this update?

Following this admission, the total number of GSK Ordinary Shares admitted to trading is 4,316,292,310. This figure includes the additional 70,759 shares admitted during the period from 29 May 2026 to 24 July 2026 under the company’s share save plan.

What type of securities did GSK (GSK) add to its London listing?

GSK added Ordinary Shares of 31¼ pence each to its London Stock Exchange Main Market listing. The 70,759 new shares admitted are of the same class and are fully fungible with existing Ordinary Shares already trading under ISIN GB00BN7SWP63.

Which employee plan is linked to GSK (GSK)’s newly admitted shares?

The newly admitted shares are linked to the “GlaxoSmithKline plc Share Save Plan 2022”. Under this plan, 70,759 Ordinary Shares were admitted to trading using existing block listing admissions, covering activity between 29 May 2026 and 24 July 2026.

Over what period were the new GSK (GSK) shares admitted to trading?

The admission to trading of 70,759 additional Ordinary Shares relates to the period from 29 May 2026 to 24 July 2026. During this date range, shares arising under the 2022 share save plan were brought onto the London Stock Exchange Main Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 10:13 AM Accepted by SEC EDGAR 07/24/2026 - 10:12 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 24 July 2026, London UK

Admission to trading

In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each ('Ordinary Shares') have been admitted to trading as set out in the table below. The Ordinary Shares have been admitted to trading under existing block listing admissions of Ordinary Shares in connection with the "GlaxoSmithKline plc Share Save Plan 2022".

1a	Issuer name	GSK plc
1b	Issuer LEI	5493000HZTVUYLO1D793
2	Regulated market on which the securities have been admitted to trading	London Stock Exchange - Main Market
3	Name, type and ISIN of the securities	Ordinary Shares of 31¼ pence each ISIN: GB00BN7SWP63
4	Number of further securities admitted to trading covered by this notification	70,759
5	Total number of securities admitted to trading following admission	4,316,292,310
6	Fungibility	Fully fungible with existing Ordinary Shares
7	Date range covered by the notification	29 May 2026 - 24 July 2026
8	Prospectus information	N/A

V A Whyte

Company Secretary

24 July 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: July 24, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc